Biomarkers of Venous Thromboembolism Recurrence after Discontinuation of Low Molecular Weight Heparin Treatment for Cancer-Associated Thrombosis (HISPALIS-Study)

SIMPLE SUMMARY: The duration of anticoagulant treatment for venous thromboembolism in cancer patients is not well defined. The decision to suspend or re-introduce anticoagulation is based on an individual assessment between thrombotic and hemorrhagic risk. In this study, three biomarkers have shown...

Descripción completa

Detalles Bibliográficos
Autores principales: Otero, Remedios, Solier-López, Aurora, Sánchez-López, Verónica, Oto, Julia, Arellano, Elena, Marín, Samira, Jara-Palomares, Luis, Elías, Teresa, Asencio, María Isabel, Blasco-Esquivias, Isabel, Rodríguez de la Borbolla, María, Sánchez-Díaz, José María, Real-Domínguez, Macarena, García-Cabrera, Emilio, Rodríguez-Martorell, Francisco Javier, Medina, Pilar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9179374/
https://www.ncbi.nlm.nih.gov/pubmed/35681751
http://dx.doi.org/10.3390/cancers14112771

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9179374/
https://www.ncbi.nlm.nih.gov/pubmed/35681751
http://dx.doi.org/10.3390/cancers14112771

Ejemplares similares